CRISPR Therapeutics doses first patient in Phase 2 thrombosis trial

ZUG, Switzerland/BOSTON - CRISPR Therapeutics (NASDAQ:CRSP), a $5.67 billion biotechnology company with strong financial health indicators according to InvestingPro data, and Sirius Therapeutics announced Monday that the first patient has been dosed in a Phase 2 clinical trial of SRSD107, a Factor XI small interfering RNA therapy for venous thromboembolism prevention in patients undergoing total knee arthroplasty.

The randomized, multicenter global study will evaluate the safety and efficacy of SRSD107, which is designed to selectively inhibit Factor XI, a key driver of pathological blood clot formation, while minimizing impact on normal blood clotting processes. The company approaches this trial from a position of financial strength, maintaining more cash than debt on its balance sheet and a remarkable current ratio of 16.61.

In previous Phase 1 trials conducted in Australia and China, single doses of SRSD107 demonstrated reductions of over 93% in Factor XI levels, with effects lasting up to six months after administration, according to the press release statement.

"SRSD107 offers the potential to reduce pathological thrombosis while minimizing bleeding risk, with sustained but reversible pharmacodynamic effects and the possibility of infrequent dosing," said Naimish Patel, Chief Medical Officer of CRISPR Therapeutics.

The therapy is being co-developed as part of a strategic collaboration established in 2025 between CRISPR Therapeutics and Sirius Therapeutics to advance treatments for cardiovascular and clotting-related diseases. Under the agreement, the companies will share development costs and profits equally, with CRISPR Therapeutics leading U.S. commercialization and Sirius leading in Greater China. Investors tracking this development should note that CRISPR’s stock has shown strong momentum, gaining over 51% in the past six months. For deeper insights into CRISPR’s financial health and growth prospects, InvestingPro subscribers have access to over 15 additional ProTips and comprehensive analysis.

Thromboembolic disorders, which involve blood clot formation, account for approximately one in four deaths worldwide, according to data cited in the companies’ announcement.

The Phase 2 trial results will help inform dose selection for future pivotal studies as the companies evaluate SRSD107’s potential as a differentiated approach for reducing thrombotic risk in patients. With the next earnings announcement scheduled for October 29, 2025, investors can access detailed financial analysis and Fair Value estimates through InvestingPro’s comprehensive research reports, available for over 1,400 US stocks.

In other recent news, CRISPR Therapeutics reported a significant earnings miss for the second quarter of 2025, with a loss of $2.40 per share, which was substantially wider than the analyst estimate of $1.40 per share. The company’s revenue also fell short of expectations, coming in at $890,000 compared to the consensus estimate of $5.81 million. The disappointing financial results were largely attributed to higher-than-expected acquired in-process R&D expenses of $96.3 million related to a recent agreement with Sirius Therapeutics. Despite the earnings miss, H.C. Wainwright raised its price target for CRISPR Therapeutics to $80 from $65, citing a 114% increase in CASGEVY sales from the first to the second quarter of 2025.

Barclays also adjusted its price target for CRISPR Therapeutics, raising it to $56 from $42, while maintaining an Equalweight rating, following updates on the company’s Casgevy treatment. In another development, JPMorgan initiated coverage of CRISPR Therapeutics with an Overweight rating and a price target of $70, suggesting that the company is approaching several inflection points across its portfolio. These recent developments reflect a mix of optimism and caution among analysts, as they evaluate the company’s financial performance and future potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.